Abstract Number: 046 • 2023 Pediatric Rheumatology Symposium
Colchicine Adherence Among Children and Young Adults with Familial Mediterranean Fever During Treatment with interleukin-1 Inhibitors
Background/Purpose: IL-1 inhibitor are approved for familial Mediterranean fever (FMF) patients who are resistant to colchicine. However, it is imperative to continue concomitant treatment with…Abstract Number: 053 • 2023 Pediatric Rheumatology Symposium
Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine…Abstract Number: 2903 • 2019 ACR/ARP Annual Meeting
Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission
Background/Purpose: Targeting the interleukin(IL)-1 pathway with anti-IL-1 drugs is a treatment option in patients with autoinflammatory diseases like monogenic periodic fever syndromes. The study aims…Abstract Number: 1245 • 2019 ACR/ARP Annual Meeting
Efficacy of Canakinumab Treatment in Adult-onset Still’s Disease
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare auto-inflammatory condition characterized by fever, arthritis, skin rash, and multi-organ inflammation. The pathogenesis of AOSD is centrally…Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting
Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…Abstract Number: 445 • 2018 ACR/ARHP Annual Meeting
Interleukin-1β Inhibition with Canakinumab Associates with Reduced Rates of Total Hip and Knee Replacement (THR/TKR) and Osteoarthritis (OA) Symptoms: Exploratory Results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Background/Purpose: In osteoarthritis (OA), there are no therapeutics to prevent disease progression. Canakinumab, a monoclonal antibody targeting interleukin-1β, reduced inflammation and cardiovascular events in the…Abstract Number: 1411 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Different Doses of Canakinumab (<2, 2–<4, and 4–<8 mg/kg) in Patients Aged <4–≥65 Years: Results from the β-Confident Registry
Background/Purpose: Canakinumab (CAN), a human anti-interleukin-1 monoclonal antibody, has shown to be efficacious and safe in the treatment of all phenotypes of cryopyrin-associated periodic syndrome…Abstract Number: 1414 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry
Background/Purpose: Long-term surveillance of biologic drugs is particularly important in pediatric patients(pts). Since 2001, the German Biologics JIA Registry (BIKER) is allowing to follow up…Abstract Number: 1418 • 2018 ACR/ARHP Annual Meeting
External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab
Background/Purpose: AIDAI is a novel and unique, validated patient (pt)-reported assessment tool to evaluate disease activity in familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency…Abstract Number: 368 • 2017 ACR/ARHP Annual Meeting
Evaluation of Efficacy and Safety of Opocalcium Colchicine, and Anti-IL1 Treatment in Childhood Colchicine-Resistant Familial Mediterranean Fever
Background/Purpose: The colchicine-resistant FMF (crFMF) is defined as 6 or more polyserositis attacks in the last year despite the regular usage of colchicine in the…Abstract Number: 376 • 2017 ACR/ARHP Annual Meeting
Improvement of Disease Activity in Patients with Colchicine-Resistant FMF, Hids/Mkd and TRAPS Assessed By Autoinflammatory Disease Activity Index (AIDAI): Results from a Randomized Phase III Trial
Background/Purpose: AIDAI is a novel, validated tool for the assessment of disease activity across a wide spectrum of autoinflammatory diseases including recurrent fever syndromes such…Abstract Number: 77 • 2017 Pediatric Rheumatology Symposium
Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study
Background/Purpose: Canakinumab (CAN) has been shown not to impair antibody production following vaccination in children in an open-label phase 3 study (NCT01302860).1 Here we present the…Abstract Number: 2378 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial
Background/Purpose: The pharmacokinetics (PK) of canakinumab (CAN) and total interleukin (IL)-1β kinetics have been well investigated in CAPS patients (pts).1 Here we present the PK…Abstract Number: 2380 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients Aged One to Six Years with Cryopyrin-Associated Periodic Syndromes: Results of an Open-Label, Phase III Extension Study
Background/Purpose: Cryopyrin-Associated Periodic Syndrome (CAPS), is a rare hereditary auto inflammatory disorder representing 3 phenotypes: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic…Abstract Number: 3206 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study
Background/Purpose: Canakinumab (CAN) has been shown not to impair antibody production following vaccination in children in an open-label phase 3 study (NCT01302860).1 Here we present…